Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Demographic, clinical, and QSM-related characteristics of the patient population
RRMS SPMS Whole Group
No. 21 15 36
Age (yr) 36.2 ± 5.8 49.5 ± 9.2 40.5 ± 8.0
Disease duration (yr) 9.7 ± 6.3 16.9 ± 7.0 12.7 ± 7.5
Sex (F/M) 16:5 9:6 25:11
EDSS (mean) (range) 2.0 (1.0–5.5) 5.0 (4.0–7.0) 3.0 (1.0–7.0)
No. of intracortical lesions (mean) 
    Total 4.5 ± 3.6 2.1 ± 2.6 3.5 ± 3.4
    QSM-hyperintense 2.8 ± 2.3 0.9 ± 1.2 2.0 ± 2.1
    QSM-isointense 0.6 ± 0.7 0.1 ± 0.4 0.4 ± 0.6
    QSM-hypointense 1.1 ± 1.5 0.9 ± 1.8 1.0 ± 1.6
No. of leukocortical lesions (mean) 
    Total 2.6 ± 3.1 5.0 ± 3.5 3.6 ± 3.5
    QSM-hyperintense 1.5 ± 1.8 1.9 ± 1.5 1.7 ± 1.7
    QSM-isointense 0.5 ± 0.9 0.6 ± 1.3 0.5 ± 1.1
    QSM-hypointense 0.5 ± 0.9 2.4 ± 2.4 1.3 ± 1.9
No. of total lesions (mean) 
    Total 7.1 ± 5.2 7.1 ± 5.0 7.1 ± 5.1
    QSM-hyperintense 4.2 ± 3.4 2.8 ± 2.3 3.6 ± 3.0
    QSM-isointense 1.0 ± 1.2 0.7 ± 1.3 0.9 ± 1.3
    QSM-hypointense 1.6 ± 1.8 3.3 ± 3.7 2.3 ± 2.8

	RRMS	SPMS	Whole Group
No.	21	15	36
Age (yr)	36.2 ± 5.8	49.5 ± 9.2	40.5 ± 8.0
Disease duration (yr)	9.7 ± 6.3	16.9 ± 7.0	12.7 ± 7.5
Sex (F/M)	16:5	9:6	25:11
EDSS (mean) (range)	2.0 (1.0–5.5)	5.0 (4.0–7.0)	3.0 (1.0–7.0)
No. of intracortical lesions (mean)
Total	4.5 ± 3.6	2.1 ± 2.6	3.5 ± 3.4
QSM-hyperintense	2.8 ± 2.3	0.9 ± 1.2	2.0 ± 2.1
QSM-isointense	0.6 ± 0.7	0.1 ± 0.4	0.4 ± 0.6
QSM-hypointense	1.1 ± 1.5	0.9 ± 1.8	1.0 ± 1.6
No. of leukocortical lesions (mean)
Total	2.6 ± 3.1	5.0 ± 3.5	3.6 ± 3.5
QSM-hyperintense	1.5 ± 1.8	1.9 ± 1.5	1.7 ± 1.7
QSM-isointense	0.5 ± 0.9	0.6 ± 1.3	0.5 ± 1.1
QSM-hypointense	0.5 ± 0.9	2.4 ± 2.4	1.3 ± 1.9
No. of total lesions (mean)
Total	7.1 ± 5.2	7.1 ± 5.0	7.1 ± 5.1
QSM-hyperintense	4.2 ± 3.4	2.8 ± 2.3	3.6 ± 3.0
QSM-isointense	1.0 ± 1.2	0.7 ± 1.3	0.9 ± 1.3
QSM-hypointense	1.6 ± 1.8	3.3 ± 3.7	2.3 ± 2.8